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Received 15 April 2014 Revised 16 July 2014 Accepted 16 July 2014Background: Blood pressure (BP) response after renal
denervation (RDN) is highly variable. Besides baseline BP,
no reliable predictors of response have been consistently
identified. The differences between patients showing a
major BP decrease after RDN vs. nonresponders have not
been studied so far.
Aim and methods: We identified extreme BP responders
(first quintile) and nonresponders (fifth quintile) to RDN
defined according to office or 24-h ambulatory BP in the
European Network COordinating research on Renal
Denervation database (n¼109) and compared the baseline
characteristics and BP changes 6 months after RDN in both
subsets.
Results: In extreme responders defined according to
ambulatory BP, baseline BP and BP changes 6 months after
RDN were similar for office and out-of-the office BP. In
contrast, extreme responders defined according to office
BP were characterized by a huge white-coat effect at
baseline, with dramatic shrinkage at 6 months. Compared
with nonresponders, extreme responders defined according
to office BP were more frequently women, had higher
baseline office – but not ambulatory – BP, and higher
estimated glomerular filtration rate (eGFR). In contrast,
when considering ambulatory BP decrease to define
extreme responders and nonresponders, the single relevant
difference between both subsets was baseline ambulatory
BP.
Conclusion: This study suggests a major overestimation of
BP response after RDN in extreme responders defined
according to office, but not ambulatory BP. The association
of lower eGFR with poor response to RDN is consistent
with our previous analysis. The increased proportion of
women in extreme responders may reflect sex differences
in drug adherence.
Keywords: ambulatory blood pressure, renal denervation,
resistant hypertension, responders
Abbreviations: BP, blood pressure; eGFR, estimated
glomerular filtration rate; ENCOReD, European Network
COordinating research on Renal Denervation; RDN, renal
denervationCopyright © Lippincott Williams & Wilkins. Unaut
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esistant hypertension is a blood pressure (BP) that
remains above goal in spite of the concomitant use
of antihypertensive medications from three or more
drug classes [1,2]. Preferably, the regimen should include a
diuretic and all doses should be optimal [1,2]. Depending
on the populations studied and applied methods and
definitions, the prevalence of treatment-resistant hyperten-
sion varies from 3 to 30% [2–4]. The SYMPLICITY HTN-1
and HTN-2 investigators reported a 25–30mmHg fall in
office SBP after endovascular catheter-based renal sym-
pathetic denervation (RDN) in treatment-resistant hyper-
tensive patients [5–8]. Following these results and CE
(Conformite´ Europe´enne) marking, the technique was rap-
idly deployed all over Europe, with an estimated 10–15 000
procedures performed up to now [9].
However, the SYMPLICITY HTN-1 and HTN-2 studies
have important limitations and potential biases [10–12].
In particular, in SYMPLICITY HTN-2 [6], the primary end-
point was based on office rather than ambulatory BP, white-
coat-resistant hypertension was not an exclusion criterion,
baseline ambulatory BP values were not reported, and
ambulatory BP decrease at 6 months was available in lesshorized reproduction of this article is prohibited.
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Responders vs. nonresponders to renal denervationthan 50% of patients [10]. Furthermore, BP responses to
RDN are highly variable [13] and no reliable predictor of the
BP response except for the baseline level could be ident-
ified [5–7,13]. In particular, none of the conditions associ-
ated with increased sympathetic tone, such as obesity or
renal dysfunction, forecasted a larger decline in BP in
response to RDN [5–7,13]. A recent, small, but rigorous
Norwegian trial including patients whose adherence was
demonstrated after witnessed drug intake was prematurely
stopped because of the dramatic superiority of drug-
treatment adjustment over RDN [9]. Finally, the predictable
[14,15] failure of SYMPLICITY HTN-3 [16] – a large US
randomized controlled trial including a sham procedure –
to meet its primary efficacy endpoint justifies a radical
revision of overoptimistic statements on the efficacy of
RDN. In particular, it highlights the urgent need to identify
patient’s profiles likely to benefit from RDN.
Inorder to further explore thepredictors ofBP response to
RDN, we compared the baseline characteristics and analyzed
the BP responses in extreme BP responders vs. nonrespond-
ers to RDN within the European Network COordinating
research on Renal Denervation (ENCOReD) [13].
METHODS
Patients analyzed in this study belong to the ENCOReD
cohort, including 109 consecutive patients from 10European
centers who underwent RDN for resistant hypertension, in
whom both office and ambulatory BP were available at
baseline and at 6 months of follow-up [13]. As previously
described [13], officeBP wasmeasured either by auscultation
of the Korotkoff sounds (one center) or by validated oscil-
lometric devices (nine centers). The number of office read-
ings averaged per visit ranged from two to five. All centers
used validated portable monitors to measure the ambulatory
BP according to the guidelines of the European Society of
Hypertension [2]. Extreme responders and nonresponders
according to office BP decrease were defined as patients
belonging to the first and fifth quintile of office SBP decrease,
respectively. Similarly, extreme and nonresponders accord-
ing to ambulatory BP decrease were defined as patients
belonging to the first and fifth quintile of 24-h ambulatory
SBP decrease. The white-coat effect was defined as office
minus 24-h ambulatory BP.
We used Statistical Analysis System (SAS), version 9.3;
SAS Institute, Cary, North Carolina, USA) for database
management and statistical analysis. Continuous data are
presented as mean SD and categorical data as frequencies
and percentages. We applied t tests to compare means and
to determine the significance of unadjusted within-group
BP changes (follow-up measurement subtracted from base-
line) and the x2-statistic to compare proportions. Signifi-
cance was a P value of 0.05 or less.
RESULTS
Main characteristics of extreme responders vs.
nonresponders to renal denervation
Twenty-one extreme responders and twenty-two nonres-
ponders according to office BP were identified in the whole
database. The same holds true for extreme responders andCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensionnonresponders according to 24-h ambulatory BP. Notably,
only seven of 22 patients (32%) classified as nonresponders
according to office BP were also nonresponders according
to ambulatory BP. Similarly, only nine of 21 patients (43%)
classified as extreme responders according to office BP
were also extreme responders according to ambulatory
BP. Extreme responders defined according to office BP
differed from nonresponders by a much higher baseline
office, but not ambulatory BP, a two-fold higher proportion
of women (71 vs. 36% in nonresponders), and a signifi-
cantly lower plasma creatinine and higher estimated glo-
merular filtration rate (eGFR). Extreme responders defined
according to 24-h ambulatory BP differed from nonres-
ponders by a significantly higher baseline ambulatory
BP, but not office BP, and a trend to decrease in the number
of antihypertensive drugs at 6 months vs. an increase in
nonresponders. Neither age nor BMI or type 2 diabetes
appeared as predictors of response in either analysis
(Table 1).
Analysis of SBP before and 6 months after
renal denervation
Extreme responders and nonresponders according
to office blood pressure
In extreme responders defined according to office BP,
baseline office SBP was 32mmHg higher than 24-h ambu-
latory SBP, whereas this difference was only 8 mmHg in
nonresponders, suggesting a major white-coat effect in the
extreme responders subgroup. Six months after RDN, mean
office SBP decreased by 52mmHg in extreme responders,
whereas 24-h ambulatory SBP decreased by only 16mmHg
(31% of office BP decrease), leading to a dramatic shrinkage
of the difference between office and ambulatory SBP
at 6 months (–4mmHg). In nonresponders, office SBP
increased by 12mmHg, whereas ambulatory SBP remained
unchanged (0.4 mmHg, NS), leading to an increase in the
difference between office and ambulatory SBP at 6 months
(Fig. 1a and b).
Extreme responders and nonresponders according
to 24-h ambulatory blood pressure
In extreme responders defined according to ambulatory BP,
baseline office SBP was only 9mmHg higher than 24-h
ambulatory SBP, a difference similar to that observed in
nonresponders (17 mmHg). Office and ambulatory SBP
decreases were similar (34 vs. 31 mmHg). In nonrespond-
ers, office SBP remained unchanged (7mmHg, NS),
whereas ambulatory SBP increased by 14mmHg (Fig. 1c
and d).
Analysis of DBP before and 6 months after
renal denervation
DBP changes after RDN largely followed those of SBP in the
different subgroups.
Extreme responders and nonresponders according
to office blood pressure
In extreme responders defined according to office BP,
baseline office DBP was 9 mmHg higher than 24-horized reproduction of this article is prohibited.
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TABLE 1. Characteristics of extreme responders and nonresponders to RDN according to the changes in office or 24-h ambulatory BP
Baseline characteristics
Office SBP 24-h Ambulatory SBP
Extreme responders Nonresponders Extreme responders Nonresponders
Number of patients, n 21 22 21 22
Baseline office SBP (mmHg) 188.328.6 158.317.3z 174.525.7 170.823.1
Baseline 24-h ambulatory SBP (mmHg) 155.819.8 150.414.1 165.015.9 153.717.6
Nonwhite ethnicity, n (%) 1 (4.8) 1 (4.6) 1 (4.8) 1 (4.6)
Women, n (%) 15 (71.4) 8 (36.4) 13 (61.9) 10 (45.4)
Diabetes mellitus, n (%) 3 (14.3) 3 (13.6) 5 (23.8) 6 (27.3)
Previous cardiovascular disease
Coronary heart disease, n (%) 4 (19.0) 5 (22.7) 4 (19.0) 2 (9.1)
Stroke, n (%) 2 (9.5) 5 (22.7) 2 (9.5) 2 (9.1)
Age (years) 58.913.4 62.010.9 57.612.4 54.810.7
BMI (kg/m2) 27.54.9 27.74.5 28.24.0 29.86.5
Plasma creatinine (mmol/l) 80.423.8 101.930.7 73.416.0 87.034.6
eGFR (ml/min per 1.73m2) 80.923.8 66.517.0 85.824.7 87.131.3
Number of antihypertensive drugs, baseline 4.21.8 4.71.5 4.81.1 4.91.3
Number of antihypertensive drugs, 6 months 3.41.7 4.22.1 3.71.1 5.01.8
Change of number of drugs –0.91.1 –0.51.3 –1.00.3 0.11.2
BP, blood pressure; eGFR, glomerular filtration rate estimated according to the Modification of Diet in Renal Disease (MDRD) formula; RDN, renal denervation. Extreme responders and
nonresponders were defined as first and fifth quintiles according to the changes in office and 24-h ambulatory blood pressure.
P<0.05 – difference between responders and nonresponders.
zP<0.001 – difference between responders and nonresponders.
Persu et al.ambulatory DBP, whereas this difference was only 1mmHg
when response was defined according to ambulatory BP.
Six months after RDN, mean office and ambulatory
DBP decreased by 22 and 12mmHg, respectively, withCopyright © Lippincott Williams & Wilkins. Unaut
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1mmHg. In nonresponders, office DBP increased by
5mmHg, whereas ambulatory DBP remained unchanged
(þ2mmHg, NS) (Fig. 2a and b).horized reproduction of this article is prohibited.
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Responders vs. nonresponders to renal denervationExtreme responders and nonresponders according
to 24-h ambulatory blood pressure
In extreme responders defined according to ambulatory BP,
both baseline DBP and DBP decrease 6 months after RDN
were similar at the office and on 24-h monitoring. In non-
responders, office DBP remained unchanged (0.7 mmHg,
NS), whereas ambulatory DBP increased by 8mmHg
(Fig. 2c and d).Analysis of heart rate before and 6 months
after renal denervation
The evolution of heart rate before and after RDN could
be analyzed in one center (Brussels), which contri-
buted to one-quarter of patients included in this
study (17 of 67). In the latter, baseline heart rate was
significantly higher in extreme responders compared
with nonresponders defined according to ambulatory
BP (94.2 12.8 vs. 68.7 14.9 mmHg, P¼ 0.016). A
similar trend was observed when response was defined
according to office BP (82.0 20.3 vs. 64.8 12.9 mmHg,
P¼ 0.12). This difference disappeared 6 months
after RDN, mostly because of a decrease in heart rate
in extreme responders (80.2 15.3 vs. 73.7 15.8,
P¼ 0.51 and 68.7 12.3 vs. 67.9 11.5, P¼ 0.92, respect-
ively).Copyright © Lippincott Williams & Wilkins. Unauth
Journal of HypertensionDISCUSSION
We report for the first time the characteristics of extreme
responders vs. nonresponders to RDN defined according to
office or ambulatory BP change in a European database of
109 consecutive patients with resistant hypertension, and
analyze the BP changes 6 months after RDN in the corre-
sponding subgroups. The association of nonresponder
status with lower eGFR is consistent with our previous
findings showing less BP decrease with lower baseline
eGFR [13]. Notably also, prespecified analysis performed
in the SYMPLICITY HTN-3 trial [16] suggest a borderline
significant (P¼ 0.05) advantage of RDN over sham in
patients with eGFR greater than 60ml/min per 1.73 m2,
but not in patients with lower eGFR. Even though it was
hypothesized that patients with chronic kidney disease may
be prime candidates for RDN because of increased sym-
pathetic activity [17], in the setting of resistant hypertension,
altered renal function may prove a surrogate marker of
irreversible renal and vascular damage, or increased
sodium retention, predicting a poor BP outcome after
RDN [13].
Another intriguing finding was that the proportion of
women was double among responders to RDN compared
with nonresponders. An increased sympathetic activity and
larger BP response to RDN in women than in men areorized reproduction of this article is prohibited.
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Persu et al.possible, but not supported by the current literature. If this
was the case, such a difference should also have been found
between extreme responders and nonresponders defined
according to ambulatory BP. Even though a chance finding
cannot be excluded, a sex difference in drug adherence is
an attractive explanation. Indeed, some studies reported
that female sex was associated with different drug adher-
ence and persistence patterns than in men [18–22]. Admit-
tedly, however, these differences were found in the
subgroups defined according to office BP, not ambulatory
BP, and need replication and confirmation in larger
study samples.
Most importantly, agreement between extreme respond-
ers defined according to either office or ambulatory BP
changes after RDN was poor. Furthermore, in extreme
responders defined according to office – but not ambulat-
ory – BP, a major discrepancy between office and ambu-
latory BP was observed at baseline, with subsequent
dramatic shrinkage of the corresponding difference at
6 months, suggesting a major overestimation of office BP
decrease after RDN. The latter likely reflects the overesti-
mation of office BP at baseline, or underestimation of office
BP at 6 months, because of regression to the mean, the
Hawthorne effect, physician-related biases, and possibly
other unidentified confounders [14]. In contrast, extreme
responders defined according to ambulatory BP had similar
baseline office and ambulatory BP, and showed an almost
identical BP decrease (30/17 mmHg) 6 months after RDN.
Our findings suggest that extreme responders defined
according to ambulatory BP, not office BP, are the ‘true’
responders to RDN. In this respect, the lack of relevant
differences between extreme responders and nonrespond-
ers defined according to ambulatory BP raises further con-
cerns about the nature and specificity of the mechanisms
underlying BP changes after RDN. Nevertheless, the finding
of a significantly higher baseline heart rate in ‘true’ extreme
responders as defined according to ambulatory BP com-
pared with nonresponders is consistent with a higher
sympathetic drive and deserves to be studied more in depth
in upcoming studies.
Admittedly, the validity of our study is limited by the
small number of patients in the different subgroups, obser-
vational character, and lack of control group and replication
sample. However, extreme responders and nonresponder
subgroups were drawn from a cohort of consecutive
patients carefully selected in 10 European expert centers,
including the whole spectrum of BP response to RDN. The
representative character of our cohort and rigor of BP
measurements are further confirmed by the similarity of
BP decrease in ENCOReD [13] and in the RDN arm of
SYMPLICITY HTN-3 [16], both for office (17.6 vs.
14.1 mmHg, respectively) and 24-h ambulatory BP (5.9
vs. 6.8 mmHg, respectively).
Compared with office measurement, ambulatory BP
measurement reduces observer bias and measurement
error, minimizes the white-coat effect and has greater
reproducibility, and therefore provides a better estimate
of a patient’s usual BP and cardiovascular prognosis
[23–25]. This statement also holds true for drug-resistant
hypertension [26]. Changes in drug adherence – a fre-
quent phenomenon in patients with apparently resistantCopyright © Lippincott Williams & Wilkins. Unaut
2426 www.jhypertension.comhypertension – may influence the results of RDN trials in
unpredictable directions [10]. Finally, our results support
previous findings [13,16], suggesting that patients with
altered renal function may not be good responders to
RDN. Accordingly, upcoming studies assessing the efficacy
of RDN should be based on ambulatory BP, incorporate
serial assessment of drug adherence using state-of-the-art
methods, and probably focus on patients with normal
renal function.
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Reviewer 1
The paper by Persu and coworkers highlights the import-
ance of ambulatory blood pressure in assessing the blood
pressure responses to renal denervation. Strengths are
represented by the rigorous experimental design adopted
as well as the careful evaluation of blood pressure changes.
A possible limitation is the lack of data on reproducibility
of the blood pressure responses following the intervention.
Reviewer 2
The present study evaluated the clinical and BP character-
istics of patients who were excellent responders to renaldenervation (RDN) and nonresponders to RDN. The data
shows a major discrepancy between office and ambulatory
BP in excellent responders to RDN suggesting a major
white-coat effect at baseline in good responders. This
was not the case in nonresponders. This indicates that
the white-coat effect is an important confounding factor
at baseline, which thus overestimates the effect of RDN.
The authors found an increased proportion of women in
responders according to office BP. Interestingly, the pres-
ence of chronic kidney disease was associated with a
reduced efficacy of RDN. In conclusion, ambulatory BP
monitoring should be performed in all patients to be
submitted to RDN.orized reproduction of this article is prohibited.
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